ID
22685
Beschrijving
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus
Trefwoorden
Versies (2)
- 07-06-17 07-06-17 -
- 09-06-17 09-06-17 -
Geüploaded op
9 juni 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
Similar models
STUDY DRUG ADMINISTRATION DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330
C0229089 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0229090 (UMLS CUI [2,2])
C0032042 (UMLS CUI [2])
C0011008 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C0042164 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0234632 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0578862 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C2880797 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C3714514 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0038901 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])